Inluriyo™

Description

Inluriyo™ (imlunestrant)

Inluriyo™ is a next-generation oral endocrine therapy designed to treat advanced ER-positive, HER2-negative breast cancer with ESR1 mutations.

As a selective estrogen receptor degrader (SERD), Inluriyo works by targeting and breaking down estrogen receptors that fuel cancer cell growth, helping slow disease progression in patients whose cancer has become resistant to prior hormone therapy. (Drugs.com)

Key Benefits

• Targets ER-positive, HER2-negative advanced or metastatic breast cancer
• Specifically designed for cancers with ESR1 mutations
• Helps overcome endocrine therapy resistance
• Convenient once-daily oral tablet
• Precision oncology treatment guided by biomarker testing
• Supports progression control in previously treated patients (Drugs.com)

How It Works

Inluriyo contains imlunestrant, an oral SERD that binds to estrogen receptors on cancer cells and causes them to break down. This blocks estrogen-driven signaling pathways that promote tumor growth and survival. (European Medicines Agency (EMA))

Indication

Inluriyo is approved for adults with:

• ER-positive
• HER2-negative
• ESR1-mutated advanced or metastatic breast cancer

whose disease has progressed following prior endocrine therapy. (European Medicines Agency (EMA))

Administration

• Taken once daily by mouth
• Administered on an empty stomach
• Continued until disease progression or unacceptable side effects occur
• Requires confirmed ESR1 mutation testing before treatment begins (Drugs.com)

Why Choose Inluriyo

Inluriyo represents a modern precision medicine approach for hormone receptor-positive breast cancer, offering targeted estrogen receptor degradation for patients whose disease no longer responds to traditional endocrine therapies. (Drugs.com)

Important Safety Information

Common side effects may include:

• Fatigue
• Nausea
• Muscle and joint pain
• Diarrhea
• Changes in blood counts and liver tests

Inluriyo may also cause embryo-fetal harm and should be used under specialist oncology supervision. (Drugs.com)